Evaluation of a multidisciplinary lipid clinic to improve the care of individuals with severe lipid conditions: a RE-AIM framework analysis
- PMID: 33741054
- PMCID: PMC7977494
- DOI: 10.1186/s43058-021-00135-8
Evaluation of a multidisciplinary lipid clinic to improve the care of individuals with severe lipid conditions: a RE-AIM framework analysis
Abstract
Background: Individuals with complex dyslipidemia, or those with medication intolerance, are often difficult to manage in primary care. They require the additional attention, expertise, and adherence counseling that occurs in multidisciplinary lipid clinics (MDLCs). We conducted a program evaluation of the first year of a newly implemented MDLC utilizing the RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) framework to provide empirical data not only on program effectiveness, but also on components important to local sustainability and future generalizability.
Methods: The purpose of the MDLC is to increase the uptake of guideline-based care for lipid conditions. Established in 2019, the MDLC provides care via a centralized clinic location within the healthcare system. Primary care providers and cardiologists were invited to refer individuals with lipid conditions. Using a pre/post-study design, we evaluated the implementation outcomes from the MDLC using the RE-AIM framework.
Results: In 2019, 420 referrals were made to the MDLC (reach). Referrals were made by 19% (148) of the 796 active cardiology and primary care providers, with an average of 35 patient referrals per month in 2019 (SD 12) (adoption). The MDLC saw 83 patients in 2019 (reach). Additionally, 50% (41/82) had at least one follow-up MDLC visit, and 12% (10/82) had two or more follow-up visits in 2019 (implementation). In patients seen by the MDLC, we found an improved diagnosis of specific lipid conditions (FH (familial hypercholesterolemia), hypertriglyceridemia, and dyslipidemia), increased prescribing of evidence-based therapies, high rates of medication prior authorization approvals, and significant reductions in lipid levels by lipid condition subgroup (effectiveness). Over time, the operations team decided to transition from in-person follow-up to telehealth appointments to increase capacity and sustain the clinic (maintenance).
Conclusions: Despite limited reach and adoption of the MDLC, we found a large intervention effect that included improved diagnosis, increased prescribing of guideline-recommended treatments, and clinically significant reduction of lipid levels. Attention to factors including solutions to decrease the large burden of unseen referrals, discussion of the appropriate number and duration of visits, and sustainability of the clinic model could aid in enhancing the success of the MDLC and improving outcomes for more patients throughout the system.
Keywords: Cardiology; Hyperlipidemia; Implementation science; RE-AIM.
Conflict of interest statement
The authors declare that they have no competing interests.
Similar articles
-
Community-based care for the specialized management of heart failure: an evidence-based analysis.Ont Health Technol Assess Ser. 2009;9(17):1-42. Epub 2009 Nov 1. Ont Health Technol Assess Ser. 2009. PMID: 23074521 Free PMC article.
-
A randomized matched-pairs study of feasibility, acceptability, and effectiveness of systems consultation: a novel implementation strategy for adopting clinical guidelines for Opioid prescribing in primary care.Implement Sci. 2018 Jan 25;13(1):21. doi: 10.1186/s13012-018-0713-1. Implement Sci. 2018. PMID: 29370813 Free PMC article. Clinical Trial.
-
The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.JBI Libr Syst Rev. 2009;7(3):80-129. doi: 10.11124/01938924-200907030-00001. JBI Libr Syst Rev. 2009. PMID: 27820426
-
Assessing Digital Health Implementation for a Pediatric Chronic Pain Intervention: Comparing the RE-AIM and BIT Frameworks Against Real-World Trial Data and Recommendations for Future Studies.J Med Internet Res. 2020 Sep 1;22(9):e19898. doi: 10.2196/19898. J Med Internet Res. 2020. PMID: 32870158 Free PMC article.
-
Clinical Practice Guideline: Nosebleed (Epistaxis) Executive Summary.Otolaryngol Head Neck Surg. 2020 Jan;162(1):8-25. doi: 10.1177/0194599819889955. Otolaryngol Head Neck Surg. 2020. PMID: 31910122 Review.
Cited by
-
Impact of a Population Genomic Screening Program on Health Behaviors Related to Familial Hypercholesterolemia Risk Reduction.Circ Genom Precis Med. 2022 Oct;15(5):e003549. doi: 10.1161/CIRCGEN.121.003549. Epub 2022 Jul 12. Circ Genom Precis Med. 2022. PMID: 35862023 Free PMC article.
-
Optimizing communication strategies and designing a comprehensive program to facilitate cascade testing for familial hypercholesterolemia.BMC Health Serv Res. 2023 Apr 5;23(1):340. doi: 10.1186/s12913-023-09304-y. BMC Health Serv Res. 2023. PMID: 37020233 Free PMC article.
-
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia.Nat Rev Cardiol. 2023 Dec;20(12):845-869. doi: 10.1038/s41569-023-00892-0. Epub 2023 Jun 15. Nat Rev Cardiol. 2023. PMID: 37322181 Review.
-
Life Course Approach for Managing Familial Hypercholesterolemia.J Am Heart Assoc. 2025 Apr;14(7):e038458. doi: 10.1161/JAHA.124.038458. Epub 2025 Mar 21. J Am Heart Assoc. 2025. PMID: 40118807 Free PMC article. Review.
-
Awareness and knowledge of heterozygous familial hypercholesterolemia among Serbian pediatricians.Front Pediatr. 2023 Feb 7;11:1096478. doi: 10.3389/fped.2023.1096478. eCollection 2023. Front Pediatr. 2023. PMID: 36824651 Free PMC article.
References
-
- Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. Jama. 2016;316(12):1289–1297. doi: 10.1001/jama.2016.13985. - DOI - PubMed
-
- Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;139(25):e1082–ee143. - PMC - PubMed
-
- Konzem SL, Gray DR, Kashyap ML. Effect of pharmaceutical care on optimum colestipol treatment in elderly hypercholesterolemic veterans. Pharmacotherapy. 1997;17(3):576–583. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous